Bilateral Panuveitis in a Patient on Vemurafenib BRAF Inhibitor Therapy for Stage IV Melanoma. Issue 4 (July 2014)

• Record Type: Journal Article
• Authors: Agemy, Steven A.; Mehta, Ankur N.; Pachydaki, Sophia I.; Tewari, Asheesh
• Is Part Of: European journal of ophthalmology. Volume 24:Issue 4(2014)
• Page Start: 629
• Page End: 632
• Publication Date: 2014-07
• Subjects: Macular edema -- Retinal disease -- Uveitis -- Vemurafenib; Ophthalmology -- Periodicals; Eye -- Diseases -- Periodicals; 617.7005
• DOI: 10.5301/ejo.5000423
• Languages: English
• ISSNs: 1120-6721

Abstract

Purpose: To describe a case of recurrent, bilateral panuveitis caused by the BRAF proto-oncogene inhibitor vemurafenib. Methods: Case report. Results: A 25-year-old woman developed bilateral panuveitis and macular edema after initiating treatment with the BRAF enzyme inhibitor vemurafenib for stage IV cutaneous melanoma. The patient was successfully treated with sub-Tenon triamcinolone injections along with cessation of the medication. Conclusions: Panuveitis is a potential adverse effect of vemurafenib. Good communication with oncology is necessary, in case the medication needs to be discontinued.